

Byong Chul Yoo
Curriculum Vitae

PERSONAL DATA

Date of Birth : August 3rd, 1971
Sex : Male
Place of Birth : Seoul, Korea
TEL : +82-31-920-2342 /FAX : +82-31-920-2354
E-mail : yoo_akh@ncc.re.kr

EDUCATION

Ph.D: November, 2001
Department of Biochemistry, University of Vienna, Vienna, Austria

MS: June, 1998
Department of Genetic Engineering, Sungkyunkwan University,
Graduate School, Seoul, Korea

BS: February, 1996
Department of Genetic Engineering, Sungkyunkwan University
Seoul, Korea

POSTGRADUATE & FACULTY APPOINTMENTS

Adjunct Professor: From January 1, 2011 to Present
Department of Genetic Engineering
Sungkyunkwan University

Proteomics Core Chief: From June 1, 2007 to Present
Proteomics Core
Research Institute, National Cancer Center, Korea

Branch Chief: From September 1, 2004 to August 31, 2005
Colorectal Cancer Branch, Division of Common Cancers,
Research Institute, National Cancer Center, Korea

Principal Investigator: From November 1, 2002 to Present
Colorectal Cancer Branch, Division of Common Cancers,

Research Institute, National Cancer Center, Korea

Research Fellow: From August 1, 2002 to October 31, 2002
Research Institute, National Cancer Center, Korea

Postdoc: From January 1, 2002 to May 31, 2002
Department of Pharmacology, School of Medicine,
Yale University

HONORS

1998 Fellowship from International Society for Amino Acids Research

2005 NCC Distinguished Publication Award 2005

2010 Meritorious Service Award in the 10th anniversary of the founding of NCC, Korea

2010 Evaluation Board for National Technology in the Ministry of Education, Science
and Technology

PUBLICATION

Byeon SE, Yu T, Yang Y, Lee YG, Kim JH, Oh J, Jeong HY, Hong S, **Yoo BC**, Cho WJ, Hong S, Cho JY. (2013) Hydroquinone regulates hemoxygenase-1 expression via modulation of Src kinase activity through thiolation of cysteine residues. *Free Radic Biol Med*. 2013 Jan 2. In Press

Kim SJ, Kim KH, Ahn ER, **Yoo BC**, Kim SY. (2013) Depletion of cathepsin D by transglutaminase 2 through protein cross-linking promotes cell survival. *Amino Acids*. 44(1):73-80.

Yu T, Moh SH, Kim SB, Yang Y, Kim E, Lee YW, Cho CK, Kim KH, **Yoo BC**, Cho JY, Yoo HS. (2013) HangAmDan-B, an Ethnomedicinal Herbal Mixture, Suppresses Inflammatory Responses by Inhibiting Syk/NF- κ B and JNK/ATF-2 Pathways. *J Med Food*. 16(1):56-65.

Li Y, Park J, Piao L, Kong G, Kim Y, Park KA, Zhang T, Hong J, Hur GM, Seok JH, Choi SW, **Yoo BC**, Hemmings BA, Brazil DP, Kim SH, Park J. (2013) PKB-mediated PHF20 phosphorylation on Ser291 is required for p53 function in DNA damage. *Cell Signal*. 25(1):74-84.

Kim KH, Yeo SG, Kim WK, Kim DY, Yeo HY, Hong JP, Chang HJ, Park JW, Kim SY, Kim BC, **Yoo BC**. (2012) Up-regulated expression of I-caldesmon associated with malignancy of colorectal cancer. *BMC Cancer*. 12(1):601.

Kim SH, Kim KH, **Yoo BC**, Ku JL. (2012) Induction of LGR5 by H₂O₂ treatment is associated with cell proliferation via the JNK signaling pathway in colon cancer cells. *Int J Oncol*. 41(5):1744-50.

Byeon SE, Yi YS, Oh J, **Yoo BC**, Hong S, Cho JY. (2012) The role of SRC kinase in macrophage-mediated inflammatory responses. *Mediators Inflamm*. 2012:512926.

Yeo SG, Kim DY, Kim KH, Ku JL, Kim JS, Cho MJ, Kim ES, **Yoo BC**. (2012) Hydroxymethylglutaryl-coenzyme a synthase 2 expression is associated with chemoradiotherapy responses in colorectal cancer. *Dis Colon Rectum*. 55(6):686-94.

Kim YJ, Park SJ, Choi EY, Kim S, Kwak HJ, **Yoo BC**, Yoo H, Lee SH, Kim D, Park JB, Kim JH. (2011) PTEN modulates miR-21 processing via RNA-regulatory protein RNH1. *PLoS One*. 6(12):e28308.

Park YS, Yoo CW, Lee SC, Park SJ, Oh JH, **Yoo BC**, Paik SS, Lee KG, Jin SY, Kim SC, Kim KP, Kim YH, Choi D, Kim HK. (2011) Lipid profiles for intrahepatic cholangiocarcinoma identified using matrix-assisted laser desorption/ionization mass spectrometry. *Clin Chim Acta*. 412(21-22):1978-82.

Choi JY, Jeong JM, **Yoo BC**, Kim K, Kim Y, Yang BY, Lee YS, Lee DS, Chung JK, Lee MC. (2011) Development of ⁶⁸Ga-labeled mannosylated human serum albumin (MSA) as a lymph node imaging agent for positron emission tomography. *Nucl Med Biol*. 38(3):371-9.

Kim SJ, **Yoo BC**, Uhm CS, Lee SW. (2011) Posttranslational arginine methylation of lamin A/C during myoblast fusion. *Biochim Biophys Acta*. 1814(2):308-17. (Co-First authorship)

Byeon SE, Lee J, **Yoo BC**, Sung GH, Kim TW, Park HJ, Cho JY. (2011) p38-Targeted inhibition of interleukin-12 expression by ethanol extract from *Cordyceps bassiana* in lipopolysaccharide-activated macrophages. *Immunopharmacol Immunotoxicol*. 33(1): 90-6.

Kim C, Lim Y, **Yoo BC**, Won NH, Kim S, Kim G. (2010) Regulation of post-translational protein arginine methylation during HeLa cell cycle. *Biochim Biophys Acta*. 1800(9):977-85.

Jeon YK, Kim SH, Choi SH, Kim KH, **Yoo BC**, Ku JL, Park JG. (2010) Promoter hypermethylation and loss of CD133 gene expression in colorectal cancers. *World J Gastroenterol*. 16(25):3153-60.

Yoo BC, Kong SY, Jang SG, Kim KH, Ahn SA, Park WS, Park S, Yun T, Eom HS. (2010) Identification of hypoxanthine as a urine marker for non-Hodgkin lymphoma by low-mass-ion profiling. *BMC Cancer*. 2010 23;10:55.

Lee JY, Lee YG, Lee J, Yang KJ, Kim AR, Kim JY, Won MH, Park J, **Yoo BC**, Kim S, Cho WJ, Cho JY. (2010) Akt Cys-310-targeted inhibition by hydroxylated benzene derivatives is tightly linked to their immunosuppressive effects. *J Biol Chem*. 285(13):9932-48.

Ju W, **Yoo BC**, Kim IJ, Kim JW, Kim SC, Lee HP. (2009) Identification of genes with differential expression in chemoresistant epithelial ovarian cancer using high-density oligonucleotide microarrays. *Oncol Res*. 18(2-3):47-56.

Hwang SY, Yoo BC, Jung JW, Oh ES, Hwang JS, Shin JA, Kim SY, Cha SH, Han IO. (2009) Induction of glioma apoptosis by microglia-secreted molecules: The role of nitric oxide and cathepsin B. *Biochim Biophys Acta*. 1793(11):1656-68. (Co-First authorship)

Shin YK, Yoo BC, Hong YS, Chang HJ, Jung KH, Jeong SY, Park JG. (2009) Upregulation of glycolytic enzymes in proteins secreted from human colon cancer cells with 5-fluorouracil resistance. *Electrophoresis*. 30(12):2182-92. (Co-First authorship)

Yoo BC, Hong SH, Ku JL, Kim YH, Shin YK, Jang SG, Kim IJ, Jeong SY, Park JG. (2009) Galectin-3 stabilizes heterogeneous nuclear ribonucleoprotein Q to maintain proliferation of human colon cancer cells. *Cell Mol Life Sci*. 66(2):350-64.

Kim DW, Kim KH, Yoo BC, Hong SH, Lim YC, Shin YK, Park JG. (2008) Identification of mitochondrial F(1)F(0)-ATP synthase interacting with galectin-3 in colon cancer cells. *Cancer Sci*. 99(10):1884-91. (Co-First authorship)

Kang SH, Kang KW, Kim KH, Kwon B, Kim SK, Lee HY, Kong SY, Lee ES, Jang SG, **Yoo BC**. (2008) Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability. *BMC Cancer*. 8:286.

Yoo BC, Shin YK, Lim SB, Hong SH, Jeong SY, Park JG. (2008) Evaluation of calgranulin B in stools from the patients with colorectal cancer. *Dis Colon Rectum*. 51(11):1703-9.

Park JW, Shon HK, **Yoo BC**, Kim IH, Moon DW, Lee TG. (2008) Differentiation between human normal colon mucosa and colon cancer tissue using ToF-SIMS imaging technique and principal component analysis. *Applied Surface Science*. 255:1119~22.

Lee KH, Moon KJ, Kim HS, **Yoo BC**, Park S, Lee H, Kwon S, Lee ES, Yoon S. (2008) Increased cytoplasmic levels of CIS, SOCS1, SOCS2, or SOCS3 are required for nuclear translocation. *FEBS Lett*. 582(15):2319-24.

Chang HJ, **Yoo BC**, Kim SW, Lee BL, Kim WH. (2007) Significance of PML and p53

protein as molecular prognostic markers of gallbladder carcinomas. *Pathol Oncol Res.* 13(4):326-35.

Chang HJ, Lee MR, Hong SH, **Yoo BC**, Shin YK, Jeong JY, Lim SB, Choi HS, Jeong SY, Park JG. (2007) Identification of mitochondrial FoF1-ATP synthase involved in liver metastasis of colorectal cancer. *Cancer Sci.* 98(8):1184-91.

Park SY, Lee SA, Han IH, **Yoo BC**, Lee SH, Park JY, Cha IH, Kim J, Choi SW. (2007) Clinical significance of metabotropic glutamate receptor 5 expression in oral squamous cell carcinoma. *Oncol Rep.* 17(1):81-7.

Kang HC, Kim IJ, Park HW, Jang SG, Ahn SA, Yoon SN, Chang HJ, **Yoo BC**, Park JG. (2007) Regulation of MDK expression in human cancer cells modulates sensitivities to various anticancer drugs: MDK overexpression confers to a multi-drug resistance. *Cancer Lett.* 2007 247(1):40-7.

Lee E, Choi MK, Youk HJ, Kim CH, Han IO, **Yoo BC**, Lee MK, Lim SJ. (2006) 5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-trifluoromethylpyrazole acts in a reactive oxygen species-dependent manner to suppress human lung cancer growth. *J Cancer Res Clin Oncol.* 132(4):223-33.

Kim DW, Kim IJ, Kang HC, Park HW, Shin Y, Park JH, Jang SG, **Yoo BC**, Lee MR, Hong CW, Park KJ, Oh NG, Kim NK, Sung MK, Lee BW, Kim YJ, Lee H, Park JG. (2005) Mutation spectrum of the APC gene in 83 Korean FAP families. *Hum Mutat.* 26(3):281.

Kim IJ, Kang HC, Shin Y, **Yoo BC**, Yang HK, Park JG. (2005) Familial gastric cancers with Li-Fraumeni Syndrome: a case report. *World J Gastroenterol.* 11(26):4124-6.

Chang HJ, Jung KH, Kim DY, Jeong SY, Choi HS, Kim YH, Sohn DK, **Yoo BC**, Lim SB, Kim DH, Ahn JB, Kim IJ, Kim JM, Yoon WH, Park JG. (2005) Bax, a predictive marker for therapeutic response to preoperative chemoradiotherapy in patients with rectal carcinoma. *Hum Pathol.* 36(4):364-71.

Chang HJ, **Yoo BC**, Lim SB, Jeong SY, Kim WH, Park JG. (2005) Metabotropic glutamate receptor 4 expression in colorectal carcinoma and its prognostic significance. *Clin Cancer Res.* 11(9):3288-95. (Co-first authorship)

Shin YK, **Yoo BC**, Chang HJ, Jeon E, Hong SH, Jung MS, Lim SJ, Park JG. (2005) Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance. *Cancer Res.* 65(8):3162-70. (Co-first authorship)

Shin YK, Heo SC, Shin JH, Hong SH, Ku JL, **Yoo BC**, Kim IJ, Park JG. (2004) Germline mutations in MLH1, MSH2 and MSH6 in Korean hereditary non-polyposis colorectal cancer families. *Hum Mutat.* 24(4):351. Erratum in: *Hum Mutat.* 2005 25(2):224.

Yoo BC, Jeon E, Hong SH, Shin YK, Chang HJ, Park JG. (2004) Metabotropic glutamate receptor 4-mediated 5-Fluorouracil resistance in a human colon cancer cell line. *Clin Cancer Res.* 10(12 Pt 1):4176-4184.

Yoo BC, Ku JL, Hong SH, Shin YK, Park SY, Kim HK, Park JG. (2004) Decreased pyruvate kinase M2 activity linked to cisplatin resistance in human gastric carcinoma cell lines. *Int J Cancer.* 108(4):532-539.

Kang HC, Kim IJ, Park JH, Shin Y, Ku JL, Jung MS, **Yoo BC**, Kim HK, Park JG. (2004) Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. *Clin Cancer Res.* 10(1 Pt 1):272-284.

Yoo BC, Krapfenbauer K, Cairns N, Belay G, Bajo M, Lubec G. (2002) Overexpressed protein disulfide isomerase in brains of patients with sporadic Creutzfeldt-Jakob disease. *Neurosci Lett.* 334(3):196-200.

Krapfenbauer K, **Yoo BC**, Fountoulakis M, Mitrova E, Lubec G (2002) Expression patterns of antioxidant proteins in brains of patients with sporadic Creutzfeldt-Jacob disease. *Electrophoresis* 23(15):2541-2547.

Yoo BC, Lubec G. (2001) Neurobiology: p25 protein in neurodegeneration. *Nature* 411:763-764.

Yoo BC, Fountoulakis M, Cairns N, Lubec G. (2001) Changes of voltage-dependent anion-selective channel proteins VDAC1 and VDAC2 brain levels in patients with Alzheimer's disease and Down Syndrome. *Electrophoresis* 22:172-179.

Yoo BC, Cairns N, Fountoulakis M, Lubec G. (2001) Synaptosomal proteins beta-soluble n-ethylmaleimide-sensitive factor attachment protein (beta-SNAP), gamma-SNAP and synaptotagmin I in brain of patients with down syndrome and Alzheimer's disease. *Dement Geriatr Cogn Disord* 12(3):219-225.

Yoo BC, Vlkolinsky R, Engidawork E, Cairns N, Fountoulakis M, Lubec G. (2001) Differential expression of molecular chaperones in brain of patients with Down Syndrome. *Electrophoresis* 22(6):1233-1241.

Yoo BC, Kim SH, Cairns N, Fountoulakis M, Lubec G. (2001) Deranged Expression of Molecular Chaperones in Brains of Patients with Alzheimer's Disease. *Biochem Biophys Res Commun* 280(1):249-258.

Yoo BC, Fountoulakis M, Dierssen M, Lubec G. (2001) Expression patterns of chaperone proteins in cerebral cortex of the fetus with Down Syndrome: dysregulation of T-complex protein 1. *J Neural Transm Suppl* 61:321-334.

Krapfenbauer K, **Yoo BC**, Kim SH, Cairns N, Lubec G. (2001) Differential display

reveals downregulation of the phospholipid transfer protein (PLTP) at the mRNA level in brains of patients with Down Syndrome. *Life Sci* 68(18):2169-2179.

Lubec B, **Yoo BC**, Dierssen M, Balic N, Lubec G. (2001) Down syndrome patients start early prenatal life with normal cholinergic, monoaminergic and serotonergic innervation. *J Neural Transm Suppl* 61:303-310.

Bajo M, **Yoo BC**, Cairns N, Gratzner M, Lubec G. (2001) Neurofilament proteins NF-L, NF-M and NF-H in brain of patients with Down syndrome and Alzheimer's disease, *Amino Acids* 21(3):293-301.

Engidawork E, Gulesserian T, **Yoo BC**, Cairns N, Lubec G. (2001) Alteration of caspases and apoptosis-related proteins in brains of patients with Alzheimer's disease. *Biochem Biophys Res Commun* 281(1):84-93.

Gulesserian T, Engidawork E, **Yoo BC**, Cairns N, Lubec G. (2001) Alteration of caspases and other apoptosis regulatory proteins in Down syndrome, *J Neural Transm Suppl* 61:163-179.

Seidl R, Bidmon B, Bajo M, **Yoo BC**, Cairns N, LaCasse EC, Lubec G. (2001) Evidence for apoptosis in the fetal Down Syndrome brain. *J Child Neurol* 16:438-442.

Kim SH, **Yoo BC**, Broers JL, Cairns N, Lubec G. (2000) Neuroendocrine-specific protein C, a marker of neuronal differentiation, is reduced in brain of patients with down syndrome and Alzheimer's disease. *Biochem Biophys Res Commun* 276(1):329-334.

Yoo BC, Park GH, Okuda H, Takaku T, Kim S, Hwang WI. (1999) Inhibitory effect of arginine-derivatives from ginseng extract and basic amino acids on protein-arginine N-methyltransferase. *Amino Acids* 17(4):391-400.

Yoo BC, Seidl R, Cairns N, Lubec G. (1999) Heat-shock protein 70 levels in brain of patients with Down syndrome and Alzheimer's disease. *J Neural Transm Suppl* 57:315-322.

Krapfenbauer K, **Yoo BC**, Cairns N, Lubec G. (1999) Differential display reveals deteriorated mRNA levels of NADH3 (complex I) in cerebellum of patients with Down syndrome. *J Neural Transm Suppl* 57:211-220.

Yoo BC, Kang MS, Kim S, Lee YS, Choi SY, Ryu CK, Park GH, Han JS. (1998) Partial purification of protein farnesyl cysteine carboxyl methyltransferase from bovine brain. *Exp Mol Med* 30(4):227-234.

Ph.D. THESIS

Title: Assessment of Gene and Protein Expression leading to Neurodegenerative Changes in Brains of Down Syndrome, Alzheimer's Disease and Creutzfeldt-Jacob Disease Patients using Differential Display and Proteomics

Abstract

Neurodegenerative diseases create many problems for the individuals who have it, for their families and for society in general. Much has happened in recent years to improve the well-being of the individuals with neurodegenerative diseases and their place in society, and more still needs to be done. Lots of scientific efforts have tried to explain the pathological mechanism and find specific therapy for neurodegenerative diseases. In fact, an explosion of scientific and clinical knowledge about the most prevalent neurodegenerative disease, Alzheimer's disease (AD), now provides a basis for selecting targets for treatment aimed at slowing progression of dementia or delaying the onset of or preventing AD. Furthermore, extensive studies have focused to elucidate DS pathogenesis since Down Syndrome (DS) is the most frequent genetic cause of mental retardation and shows closely AD-related neuropathological changes. Compared to other neurodegenerative diseases, the population of human prion diseases is very small. However, understanding of prion pathological mechanism has become a central issue for public health because of exponential increasing of the incidence of 'new variant' Creutzfeldt-Jakob disease (vCJD) in the United Kingdom.

To investigate the abnormally expressed genes and proteins leading neurodegenerative diseases and to extend our understanding of the pathological mechanism in neurodegenerative diseases, we assessed gene and protein expression in brains of patients with DS, AD and CJD using differential display and proteomics.

Through this assessment, we were able to find obviously that deranged mRNA levels of phospholipid transfer protein (PLTP I), cyclin D2 and NADH in DS and AD brain and altered protein expression levels of beta-soluble N-ethylmaleimide-sensitive factor attachment protein (SNAP), gamma-SNAP, synaptotagmin I (SYT I), voltage-dependent anion-selective channel protein (VDAC) 1, VDAC 2 and molecular chaperone proteins. Furthermore, we found that p25 (truncated form of cdk5 activator p35) is actually down-regulated in DS and AD brain using western blot analysis. Unlike in adult DS brain, protein levels of VDAC 1, VDAC 2, molecular chaperones did not change in fetal DS brain whereas T-complex protein 1 (TCP-1) was altered. Furthermore, expression levels of proteins involving in cholinergic, monoaminergic and serotonergic systems in fetal DS brain were comparable to those of controls.

In CJD brain, eighty proteins were identified and quantified using proteomics. Amongst them, we found that dysregulated expressions of antioxidant protein 2, heat shock protein (HSP) 70 families, gamma enolase, SYT I, carbonic anhydrase II (CA II), NADH-ubiquinone oxidoreductase 75 kDa subunit, fructose-bisphosphate aldolase C, dehydropyrimidinase related protein-2 (DRP-2), aconitate hydratase, protein disulfide isomerase (PDI), glutamine synthetase, alpha enolase, phosphoglycerate mutase and phosphoglycerate kinase I. Western bolt analysis revealed that p25 protein is also down-

regulated in CJD brain, however p35 was increased. Moreover, we investigated that two more antioxidant proteins, peroxiredoxin (Prx) I and Prx II in CJD brain at protein level using western blot. Prx I protein level showed a decrease whereas Prx II was not changed. Interestingly, we found that PDI protein expression was up-regulated in CJD brain and PDI could convert PrP^C into proteinase K resistance species.

Our assessment of gene and protein expression showed that many of genes and proteins were dysregulated in brains of patients with DS, AD and CJD. These findings implicated that many of cellular functions were disrupted in DS, AD and CJD brain, i.e., deranged cellular defence mechanism (altered expression of molecular chaperones and antioxidant proteins), disrupted energy metabolism (decreased levels of NADH mRNA and NADH-ubiquinone oxidoreductase 75 kDa subunit protein), abnormal cell cycle (deranged cyclin D2 and p25 proteins), and changed metabolic flux (dysregulated VDAC 1 and VDAC 2 proteins), and these abnormalities consequently caused neuronal loss (decreased protein expression of NSE, beta-SNAP, gamma-SNAP and SYT I) and reactive gliosis (increased CA II and GFAP proteins) leading neurodegeneration. Furthermore, up-regulated PDI protein expression in CJD brain and effect of PDI on PrP^C conversion process into proteinase K resistance species suggested the possibility that PDI may be target protein in CJD therapy.

Our findings might be helpful to extend our understanding of complex neuropathological mechanism at molecular level and the finding of PDI as a potential therapeutic target protein for CJD may shed light on the development of new medicine for curing CJD.